Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer [Výhody a omezení 3D organoidů a ex vivo kultivace nádorových tkání v personalizované medicíně pro karcinom prostaty]

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00077770" target="_blank" >RIV/00159816:_____/22:00077770 - isvavai.cz</a>

Result on the web

<a href="https://www.linkos.cz/files/klinicka-onkologie/513/6140.pdf" target="_blank" >https://www.linkos.cz/files/klinicka-onkologie/513/6140.pdf</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.48095/ccko2022473" target="_blank" >10.48095/ccko2022473</a>

Result language

angličtina

Original language name

Advantages and limitations of 3D organoids and ex vivo tumor tissue culture in personalized medicine for prostate cancer [Výhody a omezení 3D organoidů a ex vivo kultivace nádorových tkání v personalizované medicíně pro karcinom prostaty]

Original language description

Background: Current in vitro model systems do not fully reflect the biological and clinical diversity of prostate cancer (PCa). Organoids are 3D in vitro cell cultures that may better recapitulate disease heterogeneity and retain parental tumor characteristics. Short-term ex vivo culture of PCa tissues may also facilitate drug testing in personalized medicine. Materials and methods: For organoid culture, we have processed both cancer and normal tissues from 50 patients who underwent radical prostatectomy or transurethral resection of the prostate. In addition, we exploited the ex vivo tissue culture technique and performed short-term chemotherapy assay using gemcitabine and Chk1 inhibitor MU380 in 10 patient samples. Results: In total, we were able to cultivate organoids from 58% of tumors (29/ 50) and 69% of normal tissue (20/ 29). Im-munohistochemical staining of two representative cases revealed cell positivity for pan-cyto-keratin confirming the presence of epithelial cells. However, the overexpression of AMACR and ERG proteins in tumors was not recapitulated in organoids. Another limitation was the propa-gation of organoids only up to 3 weeks till the first passage. Next, a short-term drug test was performed for ten patients using ex vivo tissue culture. Samples from prostatectomies mostly presented a low proliferation rate as assessed by Ki-67 staining. Another drawback of this ap-proach was inconsistent tissue morphology among particular tissue fragments. Only one case showed a high proliferation rate for drug testing and tumor tissue was present in all tested samples. In our work, we also provide an overview of recent studies and a detailed comparison of culture conditions. Conclusion: We have established cultures of both organoids and tissue fragments from PCa patient samples. However, the expression of tumor markers was not recapitulated in organoids. Inconsistent morphology among tissue fragments and low proliferation hampered the interpretation of the drug testing in most cases. Still, these approaches may be promising using tissues from metastatic castration-resistant prostate cancer. (C) 2022, Czech Medical Association J.E. Purkyne. All rights reserved.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30210 - Clinical neurology

Project

Result was created during the realization of more than one project. More information in the Projects tab.

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2022

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Klinická onkologie

ISSN

0862-495X

e-ISSN

—

Volume of the periodical

35

Issue of the periodical within the volume

6

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

9

Pages from-to

473-481

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-85143963304